Article
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
The Lancet. Oncology - 1 Mar 2013
Ascierto Paolo A, Schadendorf Dirk, Berking Carola, Agarwala Sanjiv S, van Herpen Carla Ml, Queirolo Paola, Blank Christian U, Hauschild Axel, Beck J Thaddeus, St-Pierre Annie, Niazi Faiz, Wandel Simon, Peters Malte, Zubel Angela, Dummer Reinhard
Abstract excerpt
BACKGROUND: Patients with melanoma harbouring Val600 BRAF mutations benefit from treatment with BRAF inhibitors. However, no targeted treatments exist for patients with BRAF wild-type tumours, including those with NRAS mutations. We aimed to assess the use of MEK162, a small-molecule MEK1/2 inhibitor, in patients with NRAS-mutated or Val600 BRAF-mutated advanced melanoma. METHODS: In our open-label,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.